Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Glycopyrronium bromide, Formoterol fumarate dihydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Bevespi Aerosphere contains two active substances called glycopyrronium and formoterol fumarate dihydrate. These belong to a group of medicines called long-acting bronchodilators. Bevespi Aerosphere is used to make breathing easier for adults who have a lung disease called chronic obstructive pulmonary disease (COPD). COPD is a long-term disease of the airways in the lungs, which is often caused by smoking. In COPD, the muscles around the airways tighten which makes breathing difficult. The medicine prevents the tightening of the muscles around the airways, making it easier for air to get in and out of the lungs. Bevespi Aerosphere delivers the active ingredients directly to the airways in your lungs as you breathe in. It will help to reduce the effects of COPD on your everyday life.
2.
e Bevespi Aerosphere
Do not use Bevespi Aerosphere if –
you are allergic to glycopyrronium, formoterol fumarate dihydrate or any of the other ingredients of this medicine (listed in section 6). If you are not sure, talk to your doctor or pharmacist before using Bevespi Aerosphere.
Warnings and precautions Bevespi Aerosphere is used regularly for long-term treatment of COPD. Do not use this medicine to treat a sudden attack of breathlessness or wheezing.
Immediate breathing difficulties If you get tightness of the chest, coughing, wheezing or breathlessness immediately after using Bevespi Aerosphere: Stop using this medicine and seek medical help immediately, as you may have a serious condition called paradoxical bronchospasm. Talk to your doctor or pharmacist before using Bevespi Aerosphere if
Driving and using machines
It is unlikely that this medicine will affect your ability to drive and use machines. However, dizziness and nausea are common side effects which may occur. If this occurs, do not drive or use machines.
3.
How to use Bevespi Aerosphere
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. How much to use The recommended dose is two puffs twice a day. It is important to use Bevespi Aerosphere every day, even if you have no COPD symptoms at the time.
Bevespi Aerosphere is for inhalation use. Please read the instructions for use at the end of this leaflet. If you are not sure of how to use Bevespi Aerosphere, contact your doctor or pharmacist. Using Bevespi Aerosphere with a spacer If you find it difficult breathing in and pressing the inhaler at the same time talk to your doctor or pharmacist. You may be able to use a 'spacer' with your inhaler. If you use more Bevespi Aerosphere than you should If you have used more Bevespi Aerosphere than you should, talk to a doctor or pharmacist immediately. You may need medical attention. You may notice that your heart is beating faster than usual, you feel shaky, you have visual disturbances, have a dry mouth, or have a headache or feel nauseous (sick). If you forget to use Bevespi Aerosphere Do not take a double dose to make up for a forgotten dose. Take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose. Do not take more than two puffs twice a day. If you stop using Bevespi Aerosphere This medicine is for long-term use. It will only be effective as long as you are using it. Do not stop unless your doctor tells you to, even if you feel better, as your symptoms may get worse. If you want to stop treatment, first talk to your doctor. If you have any further questions on the use of this medicine, talk to your doctor or pharmacist.
4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Serious side effects Stop using Bevespi Aerosphere and seek immediate medical care if you notice any of the following symptoms: Uncommon: may affect up to 1 in 100 people: o swelling of your face, particularly around your mouth (swelling of your tongue or throat may make it difficult to swallow);
o rash or hives together with difficulty breathing o suddenly feeling faint. These symptoms may be signs of an allergic reaction which may become serious. Other possible side effects Common: may affect up to 1 in 10 people
5.
Bevespi Aerosphere
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton, pouch and pressurised container after 'EXP'. The expiry date refers to the last day of that month. The inhaler can be used for up to 3 months after first opening the pouch. Write the date the pouch is opened on the inhaler label in the space provided. Do not store above 30oC. Warning: Do not break, puncture or burn the pressurised container, even when apparently empty. Do not expose to temperatures higher than 50oC. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6.
What Bevespi Aerosphere contains
The active substances are glycopyrronium and formoterol fumarate dihydrate. Each single puff delivers a dose of 9 micrograms glycopyrronium bromide (equivalent to 7.2 micrograms of glycopyrronium), and 5 micrograms of formoterol fumarate dihydrate. The other ingredients are norflurane, 1,2- distearoyl-sn-glycero-3-phosphocholine and calcium chloride. What Bevespi Aerosphere looks like and contents of the pack Bevespi Aerosphere is a pressurised inhalation, suspension. Bevespi Aerosphere comes as a pressurised container with a dose indicator, supplied with a white plastic actuator body and mouthpiece (see Figure 1 of the Instructions for Use at the end of this leaflet). The mouthpiece is covered with an orange protective cap. Bevespi Aerosphere is supplied in a foil pouch that contains a drying packet (desiccant) and packed into a carton. The active ingredients are present in a pressurised suspension inside the pressurised container. Bevespi Aerosphere is available in packs containing 1 inhaler with 120 puffs and in multipacks comprising 3 inhalers, each containing 120 puffs. Not all pack sizes may be marketed. Marketing Authorisation Holder AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge, CB2 0AA, UK Manufacturer AstraZeneca Dunkerque Production 224 Avenue de la Dordogne Dunkerque 59640 France
This leaflet was last revised in August 2022 © AstraZeneca 2022 BEVESPI AEROSPHERE is a registered trademark of the AstraZeneca group of companies. RSP 22 0061
Other sources of information
To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge: 0800 198 5000 Please be ready to give the following information: Product name Bevespi Aerosphere 7.2 micrograms /5 micrograms pressurised inhalation, suspension.
Reference number 17901/0309
This is a service provided by the Royal National Institute of the Blind.
Instructions for use Bevespi Aerosphere, 7.2 micrograms / 5 micrograms pressurised inhalation, suspension glycopyrronium / formoterol fumarate dihydrate
Read this instructions for use and the package leaflet before you start using Bevespi Aerosphere and each time you get a new inhaler. There may be new information. This information should be used alongside a discussion with your doctor about your medical condition and treatment. Important Information: • For inhalation use only. • Use Bevespi Aerosphere exactly as your doctor tells you to. • Talk to your doctor or pharmacist if you have any questions about the use of your inhaler. The parts of your Bevespi Aerosphere inhaler (See Figure 1): • Bevespi Aerosphere comes as a pressurised container with a dose indicator that fits into an actuator. o Do not use the Bevespi Aerosphere actuator with any other medicine. o Do not use the Bevespi Aerosphere pressurised container with an actuator from any other inhaler.
SIDE VIEW
TOP VIEW Dose indicator display window
Dose indicator
Pointer
Pressurised container
Actuator Press here
Mouthpiece Cap
Figure 1
•
Bevespi Aerosphere comes with a dose indicator on the top of the pressurised container (See Figure 1). The dose indicator display window shows how many puffs of medicine you have left. A puff of medicine is released each time you press the centre of the dose indicator.
Before you use Bevespi Aerosphere for the first time Before you use Bevespi Aerosphere for the first time, make sure that the pointer on the dose indicator is pointing to the right of the "120" inhalation mark in the dose indicator display window (See Figure 1). • The pointer points to 120 after 10 puffs are delivered from Bevespi Aerosphere. This means that there are 120 puffs of medicine left in the pressurised container (See Figure 2a). • The pointer points between 100 and 120 after you use 10 more puffs. This means that there are 110 puffs of medicine left in the pressurised container (See Figure 2b). • The pointer points to 100 after you take 10 more puffs. This means that there are 100 puffs of medicine left in the pressurised container (See Figure 2c).
Figure 2a 120 puffs •
• •
Figure 2b 110 puffs
Figure 2c 100 puffs
The dose indicator display window will move after every 10 puffs. The number in the dose indicator display window will change after every 20 puffs.
Figure 2d The colour in the dose indicator display window will change to red, as shown in the shaded area, when there are only 20 puffs of medicine left in your inhaler (See Figure 2d). When the arrow reaches '0', you must stop using your inhaler. Your inhaler may not feel empty and it may seem as though it still works. However, you will not get the right amount of medicine if you keep using it.
Preparing your Bevespi Aerosphere inhaler for use: • Your Bevespi Aerosphere inhaler comes in a foil pouch that contains a drying packet (desiccant). o Take the Bevespi Aerosphere inhaler out of the foil pouch. o Throw away the pouch and the drying packet. Do not use the inhaler if the drying agent has leaked out of its packet.
Figure 3 Priming your Bevespi Aerosphere inhaler: Before you use Bevespi Aerosphere for the first time, you must prime the inhaler. • Remove the cap from the mouthpiece (See Figure 3). Check inside the mouthpiece before you use the inhaler to make sure it is clear. • Hold the inhaler upright, away from your face and shake it well (See Figure 4).
•
• •
Figure 4 Press down firmly on the centre of the dose indicator until the pressurised container stops moving in the actuator. This will release a puff of medicine from the mouthpiece (See Figure 5). You may hear a soft click from the dose indicator as it counts down during use.
Figure 5 Repeat the priming steps 3 more times (See Figure 4 and Figure 5). Shake the inhaler well before each priming puff. After priming 4 times, the dose indicator should be pointing to the right of "120" and your inhaler is now ready to use.
Using your Bevespi Aerosphere inhaler: Step 1: Remove the cap from the mouthpiece (See Figure 6).
Figure 6 Step 2: Shake the inhaler well before each use (See Figure 7).
Figure 7 Step 3: Hold the inhaler with the mouthpiece pointing towards you and breathe out as fully as you comfortably can through your mouth (See Figure 8).
Figure 8 Step 4: Close your lips around the mouthpiece and tilt your head back, keeping your tongue below the mouthpiece (See Figure 9).
Figure 9
Step 5: While breathing in deeply and slowly, press down on the centre of the dose indicator until the pressurised container stops moving in the actuator and a puff of medicine has been released (See Figure 10). Then stop pressing the dose indicator.
Figure 10 Step 6: When you have finished breathing in, remove the mouthpiece from your mouth. Hold your breath as long as you comfortably can, up to 10 seconds (See Figure 11).
Figure 11 Step 7: Breathe out gently (See Figure 12). Repeat steps 2 to 7 to take your second puff of Bevespi Aerosphere.
Figure 12
Step 8: Replace the cap over the mouthpiece right away after use (See Figure 13).
Figure 13 How to clean your Bevespi Aerosphere inhaler: Clean the inhaler once each week for the first 3 weeks. It is very important to keep your inhaler clean so that medicine does not build-up and block the spray through the mouthpiece (See Figure 14).
Figure 14 Step 1: Take the pressurised container out of the actuator (See Figure 15). Do not clean the pressurised container or let it get wet.
Figure 15 Step 2: Take the cap off the mouthpiece. Step 3: Hold the actuator under the tap and run warm water through it for about 30 seconds. Turn the actuator upside down and rinse the actuator again through the mouthpiece for about 30 seconds (See Figure 16).
Figure 16 Step 4: Shake off as much water from the actuator as you can. Step 5: Look into the actuator and the mouthpiece to make sure any medicine build-up has been completely washed away. If there is any built-up medicine, repeat Steps 3 to 5 in the section. Step 6: Let the actuator air-dry overnight (See Figure 17). Do not put the pressurised container back into the actuator if it is still wet.
Figure 17 Step 7: When the actuator is dry, gently press the pressurised container down in the actuator (See Figure 18). Do not press down too hard on the pressurised container. This could cause a puff of medicine to be released.
Figure 18 Step 8: Re-prime your Bevespi Aerosphere inhaler after each cleaning. To re-prime the inhaler, shake the inhaler well and press down on the centre of the dose indicator twice to release a total of 2 puffs into the air away from your face. Your inhaler is now ready to use. If you do not use your Bevespi Aerosphere for more than 7 days or if exposed to low temperatures or is dropped: If you do not use your Bevespi Aerosphere for more than 7 days, or if the inhaler is exposed to low temperatures or has been dropped, you will need to re-prime it before use. To re-prime the inhaler, shake the inhaler well and press down on the centre of the dose indicator twice to release a total of 2 puffs into the air away from your face. Your inhaler is now ready to use.
Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspension comes as oral solution containing 7.2mcg / 5mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspension is glycopyrronium bromide, formoterol fumarate dihydrate.
This leaflet reproduces the patient information leaflet approved for Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspension, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) (see section 5.1).
Posology
The recommended dose is two inhalations twice daily (two inhalations in the morning and two inhalations in the evening).
Patients should be advised not to take more than 2 inhalations twice daily.
If a dose is missed, it should be taken as soon as possible and the next dose should be taken at the usual time. A double dose should not be taken to make up for a forgotten dose.
Special populations
Elderly
No dose adjustments are required in elderly patients (see section 5.2).
Renal impairment
Bevespi Aerosphere can be used at the recommended dose in patients with mild to moderate renal impairment. In patients with severe renal impairment or end-stage renal disease requiring dialysis it should be used only if the expected benefit outweighs the potential risk (see sections 4.4 and 5.2).
Hepatic impairment
Bevespi Aerosphere can be used at the recommended dose in patients with mild to moderate hepatic impairment. There are no relevant data on the use of Bevespi Aerosphere in patients with severe hepatic impairment and the medicinal product should be used with caution in these patients (see sections 4.4 and 5.2).
Paediatric population
There is no relevant use of Bevespi Aerosphere in children and adolescents (under 18 years of age) for the indication of COPD.
Method of administration
For inhalation use.
Instructions for use
On actuation of Bevespi Aerosphere, a volume of the suspension is expelled from the pressurised container at high velocity. When the patient inhales through the mouthpiece at the same time as actuating the inhaler, the substance will follow the inspired air into the airways.
Note: Patients should be instructed on the correct inhalation technique. It is important to instruct the patient to:
• Carefully read the instructions for use in the patient information leaflet, which is packed together with each inhaler.
• Not use the inhaler if the drying agent, which is inside the foil pouch, has leaked out of its packet.
• Prime the inhaler by shaking it and actuating into the air four times before first use or two times when the inhaler has not been used for more than seven days, has been exposed to low temperatures, or has been dropped.
To get adequate lung deposition of the active substances actuation must be co-ordinated with inhalation.
Patients who find it difficult to co-ordinate actuation with inspiration of breath may use Bevespi Aerosphere with a spacer to ensure proper administration of the product. Compatibility with the Aerochamber Plus Flow-Vu spacer device has been demonstrated (see section 5.2).
Hypersensitivity to the active substances or any of the excipients listed in section 6.1.
Asthma
Bevespi Aerosphere should not be used to treat asthma.
Paradoxical bronchospasm
In clinical studies, paradoxical bronchospasm was not observed with Bevespi Aerosphere at its recommended dose. If paradoxical bronchospasm does occur, treatment with the medicinal product should be stopped and other treatments considered.
Not for acute use
Bevespi Aerosphere is not indicated for the treatment of acute episodes of bronchospasm, i.e. as a rescue therapy.
Cardiovascular effects
Cardiovascular effects, such as cardiac arrhythmias e.g. atrial fibrillation and tachycardia, may be seen after the administration of muscarinic receptor antagonists and sympathomimetics, including glycopyrronium or formoterol. Patients with clinically significant uncontrolled cardiovascular disease were excluded from clinical studies. Bevespi Aerosphere should be used with caution in patients with severe cardiovascular disorders, such as ischaemic heart disease, tachyarrhythmias or severe heart failure.
Caution should also be exercised in patients with thyrotoxicosis or known or suspected prolongation of the QTc interval (see section 4.5).
Hypokalaemia
β2-adrenergic agonists may produce significant hypokalaemia, which may increase the susceptibility to cardiac arrhythmias. The decrease in serum potassium is usually transient, not requiring supplementation. In patients with severe COPD, hypokalaemia may be potentiated by hypoxia and concomitant treatment (see section 4.5).
Hyperglycaemia
Inhalation of high doses of β2-adrenergic agonists may produce increases in plasma glucose.
Anticholinergic activity
Due to its anticholinergic activity, Bevespi Aerosphere should be used with caution in patients with symptomatic prostatic hyperplasia, urinary retention or with narrow-angle glaucoma (see section 4.8).
Renal impairment
As glycopyrronium is predominantly renally excreted, patients with severe renal impairment (creatinine clearance of < 30 mL/min), including those with end-stage renal disease requiring dialysis, should only be treated with Bevespi Aerosphere if the expected benefit outweighs the potential risk (see section 5.2).
Hepatic impairment
In patients with severe hepatic impairment, Bevespi Aerosphere should be used only if the expected benefit outweighs the potential risk (see section 5.2). These patients should be monitored for potential adverse reactions.
Pharmacokinetic interactions
Clinical drug-drug interaction studies have not been conducted with Bevespi Aerosphere, however, the potential for metabolic interactions is considered to be low based on in-vitro studies (see section 5.2).
Since glycopyrronium is eliminated mainly by the renal route, drug interaction could potentially occur with medicinal products affecting renal excretion mechanisms. In-vitro glycopyrronium is a substrate for the renal transporters OCT2 and MATE1/2K. The effect of cimetidine, a probe inhibitor of OCT2 and MATE1, on inhaled glycopyrronium disposition showed a limited increase in its total systemic exposure (AUC0-t) by 22% and a slight decrease in renal clearance by 23% due to co-administration of cimetidine.
Pharmacodynamic interactions
Other antimuscarinics and sympatomimetics
Co-administration of Bevespi Aerosphere with other anticholinergic and/or long-acting β2-adrenergic agonist containing medicinal products has not been studied and is not recommended as it may potentiate known inhaled muscarinic antagonist or beta2-adrenergic agonist adverse reactions (see section 4.4 and section 4.9).
Although no formal in-vivo drug interaction studies have been performed with Bevespi Aerosphere, studies indicate no clinical evidence of interactions when used concomitantly with other COPD medicinal products including short-acting β2-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids.
Drug-induced hypokalaemia
Concomitant treatment with methylxanthine derivatives, steroids, or non-potassium-sparing diuretics may potentiate the possible initial hypokalaemic effect of β2-adrenergic agonists, therefore, caution is advised in their concomitant use (see section 4.4).
β-adrenergic blockers
β-adrenergic blockers (including eye drops) can weaken or inhibit the effect of β2-adrenergic agonists, such as formoterol. Concurrent use of either non-selective or selective β-adrenergic blockers should be avoided unless there are compelling reasons for their use. If β-adrenergic blockers are required (including eye drops), cardioselective β-adrenergic blockers are preferred, although they should also be administered with caution.
Other pharmacodynamic interactions
Bevespi Aerosphere should be administered with caution to patients being treated with medicinal products known to prolong the QTc interval (see section 4.4).
Pregnancy
There are no data on the use of Bevespi Aerosphere in pregnant women.
Single-dose studies in humans found that very small amounts of glycopyrronium passed the placental barrier. In animal studies formoterol and glycopyrronium, individually, have caused adverse effects in reproduction studies at very high doses/systemic exposure levels (see section 5.3).
Bevespi Aerosphere should only be used during pregnancy if the expected benefits outweigh the potential risks.
Breast-feeding
It is not known whether glycopyrronium or formoterol are excreted in human milk. Evidence of transfer of glycopyrronium and formoterol into maternal milk in rats has been reported.
Administration of Bevespi Aerosphere to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the infant (see section 5.3).
Fertility
Studies in rats have shown adverse effects on fertility only at dose levels higher than the maximum human exposure to formoterol (see section 5.3). Glycopyrronium did not cause any adverse effects on fertility in rats. It is unlikely that Bevespi Aerosphere administered at the recommended dose will affect fertility in humans.
Bevespi Aerosphere has no or negligible influence on the ability to drive and use machines. However dizziness and nausea are common side effects which should be taken into account when driving or using machines.
Summary of the safety profile
The safety profile is characterised by anticholinergic and β2-adrenergic class effects related to the individual components of the combination. The most common adverse reactions reported in the clinical development program (comprised of 1,588 patients receiving Bevespi Aerosphere) were headache (1.9%), nausea (1.4%), muscle spasms (1.4%), and dizziness (1.3%).
Tabulated list of adverse reactions
The tabulated list of adverse reactions is based on the experience with Bevespi Aerosphere in clinical trials and experience with the individual components and related products.
The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from available data).
Table 1 Adverse reactions by frequency and system organ class (SOC)
System Organ Class
Preferred term
Frequency
Immune system disorders
Hypersensitivity reactions including rash and pruritus
Uncommon
Metabolism and nutrition disorders
Hyperglycaemia1
Uncommon
Psychiatric disorders
Anxiety
Common
Agitation
Restlessness
Insomnia
Uncommon
Nervous system disorders
Headache1
Dizziness
Common
Tremor1
Uncommon
Cardiac disorders
Tachycardia
Palpitations
Cardiac arrhythmias (atrial fibrillation, supraventricular tachycardia, and extrasystoles)
Uncommon
Gastrointestinal disorders
Dry mouth2, Nausea
Common
Musculoskeletal and connective tissue disorders
Muscle spasms1
Common
Renal and urinary disorders
Urinary tract infection
Common
Urinary retention2
Uncommon
General disorders and administration site conditions
Chest pain
Common
1 adverse reaction relates to formoterol
2 adverse reaction relates to glycopyrronium
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme; website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
An overdose of Bevespi Aerosphere may lead to exaggerated anticholinergic and/or β2-adrenergic signs and symptoms, the most frequent of which include blurred vision, dry mouth, nausea, muscle spasm, tremor, headache, palpitations and systolic hypertension.
If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Not the same combination. This medicine contains Glycopyrronium bromide, Formoterol fumarate dihydrate. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
⚠ Not the same combination. This medicine contains Glycopyrronium bromide, Formoterol fumarate dihydrate. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspension. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.